Helicobacter pylori infection and the risks of Barrett's oesophagus: A population-based case-control study

International Journal of Cancer

Volumn 130, Issue 10, 2012, Pages 2407-2416

  Thrift, Aaron P ^a,b   Pandeya, Nirmala ^a   Smith, Kylie J ^b   Green, Adèle C ^b,c   Hayward, Nicholas K ^b   Webb, Penelope M ^b   Whiteman, David C ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Barrett's oesophagus; environmental modifiers; epidemiology; gastro oesophageal reflux; Helicobacter pylori

Indexed keywords

BACTERIUM ANTIBODY; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ANTIBODY DETECTION; ARTICLE; AUSTRALIA; BARRETT ESOPHAGUS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; DYSPLASIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SERODIAGNOSIS;

AGED; ANTIBODIES, BACTERIAL; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK;

EID: 84859099847     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26242     Document Type: Article

References (49)

1. Falk GW,. Barrett's esophagus. Gastroenterology 2002; 122: 1569-91. (Pubitemid 34533554)
2. Bosetti C, Levi F, Ferlay J, Garavello W, Lucchini F, Bertuccio P, Negri E, La Vecchia C,. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer 2008; 122: 1118-29. (Pubitemid 351214012)
3. Pohl H, Sirovich B, Welch HG,. Esophageal adenocarcinoma incidence: Are we reaching the peak? Cancer Epidemiol Biomarkers Prev 2010; 19: 1468-70.
4. Holmes RS, Vaughan TL,. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007; 17: 2-9. (Pubitemid 44918357)
5. Lord RVN, Law MG, Ward RL, Giles GG, Thomas RJS, Thursfield V,. Rising incidence of oesophageal adenocarcinoma in men in Australia. J Gastroenterol Hepatol 1998; 13: 356-62. (Pubitemid 28215942)
6. Brown LM, Devesa SS, Chow WH,. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008; 100: 1184-7.
7. Cameron AJ, Ott BJ, Payne WS,. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313: 857-9. (Pubitemid 15250200)
8. Cook MB, Wild CP, Everett SM, Hardie LJ, Bani-Hani KE, Martin IG, Forman D,. Risk of mortality and cancer incidence in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2007; 16: 2090-6. (Pubitemid 47621185)
9. Blaser MJ,. Disappearing microbiota: Helicobacter pylori protection against esophageal adenocarcinoma. Cancer Prev Res (Philadelphia) 2008; 1: 308-11.
10. Huang JQ, Sridhar S, Chen Y, Hunt RH,. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998; 114: 1169-79. (Pubitemid 28243902)
11. Ye WM, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK, Nyren O,. Helicobacter pylori infection and gastric atrophy: Risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 2004; 96: 388-96. (Pubitemid 38351300)
12. Whiteman DC, Parmar P, Fahey P, Moore SP, Stark M, Zhao ZZ, Montgomery GW, Green AC, Hayward NK, Webb PM,; Australian Cancer Study. Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology 2010; 139: 73-83.
13. Islami F, Kamangar F,. Helicobacter pylori and esophageal cancer risk: A meta-analysis. Cancer Prev Res (Philadelphia) 2008; 1: 329-38.
14. de Martel C, Llosa AE, Farr SM, Friedman GD, Vogelman JH, Orentreich N, Corley DA, Parsonnet J,. Helicobacter pylori infection and the risk of development of esophageal adenocarcinoma. J Infect Dis 2005; 191: 761-7. (Pubitemid 40271067)
15. Chow WH, Blaser MJ, Blot WJ, Gammon MD, Vaughan TL, Risch HA, Perez-Perez GI, Schoenberg JB, Stanford JL, Rotterdam H, West AB, Fraumeni JF,. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998; 58: 588-90. (Pubitemid 28099460)
16. Henrik Siman J, Forsgren A, Berglund G, Floren CH,. Helicobacter pylori infection is associated with a decreased risk of developing oesophageal neoplasms. Helicobacter 2001; 6: 310-6. (Pubitemid 34015012)
17. Jones AD, Bacon KD, Jobe BA, Sheppard BC, Deveney CW, Rutten MJ,. Helicobacter pylori induces apoptosis in Barrett's-derived esophageal adenocarcinoma cells. J Gastrointest Surg 2003; 7: 68-76. (Pubitemid 36875803)
18. McColl KE, El-Omar E, Gillen D,. Helicobacter pylori gastritis and gastric physiology. Gastroenterol Clin North Am 2000; 29: 687-703.
19. El-Omar EM, Carrington M, Chow WH, McColl KEL, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402. (Pubitemid 30164342)
20. McColl KE,. Helicobacter pylori and oesophageal cancer-Not always protective. Gut 2007; 56: 457-9. (Pubitemid 46580495)
21. El-Omar EM, Penman ID, Ardill JES, Chittajallu RS, Howie C, McColl KEL,. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109: 681-91.
22. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G,. Relationship between Helicobacter pylori infection and esophageal neoplasia: A meta-analysis. Clin Gastroenterol Hepatol 2007; 5: 1413-17.
23. Wang CC, Yuan YH, Hunt RH,. Helicobacter pylori infection and Barrett's esophagus: A systematic review and meta-analysis. Am J Gastroenterol 2009; 104: 492-500.
24. Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, Leighton P, Rumore G, Quesenberry C, Buffler P, Parsonnet J,. Helicobacter pylori infection and the risk of Barrett's oesophagus: A community-based study. Gut 2008; 57: 727-33. (Pubitemid 351716961)
25. Anderson LA, Murphy SJ, Johnston BT, Watson RGP, Ferguson HR, Bamford KB, Ghazy A, McCarron P, McGuigan J, Reynolds JV, Comber H, Murray LJ,. Relationship between Helicobacter pylori infection and gastric atrophy and the stages of the oesophageal inflammation, metaplasia, adenocarcinoma sequence: Results from the FINBAR case-control study. Gut 2008; 57: 734-9. (Pubitemid 351716963)
26. Smith KJ, O'Brien SM, Green AC, Webb PM, Whiteman DC,; Study of Digestive Health. Current and past smoking significantly increase risk for Barrett's esophagus. Clin Gastroenterol Hepatol 2009; 7: 840-8.
27. Pandeya N, Williams GM, Green AC, Webb PM, Whiteman DC,. Do low control response rates always affect the findings? Assessments of smoking and obesity in two Australian case-control studies of cancer. Aust NZ J Public Health 2009; 33: 312-19.
28. Go MF,. Review article: Natural history and epidemiology of Helicobacter pylori injection. Aliment Pharmacol Ther 2002; 16 (Suppl 1): 3-15. (Pubitemid 41759561)
29. El-Omar EM, Oien K, ElNujumi A, Gillen D, Wirz A, Dahill S, Williams C, Ardill JES, McColl KEL,. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113: 15-24. (Pubitemid 27281753)
30. Blaser MJ, Atherton JC,. Helicobacter pylori persistence: Biology and disease. J Clin Invest 2004; 113: 321-33. (Pubitemid 38544173)
31. Oksanen A, Sipponen P, Karttunen R, Miettinen A, Veijola L, Sarna S, Rautelin H,. Atrophic gastritis and Helicobacter pylori infection in outpatients referred for gastroscopy. Gut 2000; 46: 460-3. (Pubitemid 30305807)
32. Kuipers EJ, Uyterlinde AM, Pena AS, Roosendaal R, Pals G, Nelis GF, Festen HPM, Meuwissen SGM,. Long-term sequelae of helicobacter pylori gastritis. Lancet 1995; 345: 1525-8.
33. Tatsuguchi A, Miyake K, Gudis K, Futagami S, Tsukui T, Wada K, Kishida T, Fukuda Y, Sugisaki Y, Sakamoto C,. Effect of Helicobacter pylori infection on ghrelin expression in human gastric mucosa. Am J Gastroenterol 2004; 99: 2121-7. (Pubitemid 39524700)
34. Jang EJ, Park SW, Park JS, Park SJ, Hahm KB, Paik SY, Sin MK, Lee ES, Oh SW, Park CY, Baik HW,. The influence of the eradication of Helicobacter pylori on gastric ghrelin, appetite, and body mass index in patients with peptic ulcer disease. J Gastroenterol Hepatol 2008; 23 (Suppl 2): S278-85.
35. Nwokolo CU, Freshwater DA, O'Hare P, Randeva HS,. Plasma ghrelin following cure of Helicobacter pylori. Gut 2003; 52: 637-40. (Pubitemid 36528862)
36. Parente F, Maconi G, Sangaletti O, Minguzzi M, Vago L, Porro GB,. Behavior of acid secretion, gastrin release, serum pepsinogen I, and gastric emptying of liquids over six months from eradication of Helicobacter pylori in duodenal ulcer patients. A controlled study. Gut 1995; 37: 210-15.
37. Perri F, Clemente R, Festa V, Annese V, Quitadamo M, Rutgeerts P, Andriulli A,. Patterns of symptoms in functional dyspepsia: Role of Helicobacter pylori infection and delayed gastric emptying. Am J Gastroenterol 1998; 93: 2082-8. (Pubitemid 29076855)
38. Azuma T, Suto H, Ito Y, Muramatsu A, Ohtani M, Dojo M, Yamazaki Y, Kuriyama M, Kato T,. Eradication of Helicobacter pylori infection induces an increase in body mass index. Aliment Pharmacol Ther 2002; 16 (Suppl 2): 240-4. (Pubitemid 41771485)
39. Kubo A, Corley DA,. Body mass index and adenocarcinomas of the esophagus or gastric cardia: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 872-8. (Pubitemid 43823511)
40. Hampel H, Abraham NS, El-Serag HB,. Meta-analysis: Obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143: 199-211. (Pubitemid 41076753)
41. Whiteman DC, Sadeghi S, Pandeya N, Smithers BM, Gotley DC, Bain CJ, Webb PM, Green AC,; Australian Cancer Study. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 2008; 57: 173-80. (Pubitemid 351158042)
42. Cook MB, Greenwood DC, Hardie LJ, Wild CR, Forman D,. A systematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol 2008; 103: 292-300. (Pubitemid 351248722)
43. de Martel C, Haggerty TD, Corley DA, Vogelman JH, Orentreich N, Parsonnet J,. Serum ghrelin levels and risk of subsequent adenocarcinoma of the esophagus. Am J Gastroenterol 2007; 102: 1166-72. (Pubitemid 46801999)
44. Sampliner RE,. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97: 1888-95.
45. Australian Bureau of Statistics. National Health Survey: Summary of results 2007-2008. Vol cat. no. 4364.0. Released 25 August 2009. Australian Bureau of Statistics: Canberra, 2009.
46. Watson DI, Lally CJ,. Prevalence of symptoms and use of medication for gastroesophageal reflux in an Australian community. World J Surg 2009; 33: 88-94.
47. Cameron AJ, Lomboy CT,. Barrett's esophagus: Age, prevalence, and extent of columnar epithelium. Gastroenterology 1992; 103: 1241-5.
48. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA,. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990; 99: 918-22. (Pubitemid 20338445)
49. Gerson LB, Shetler K, Triadafilopoulos G,. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002; 123: 461-7. (Pubitemid 34827190)